Literature DB >> 10696240

The natural history of bladder cancer. Implications for therapy.

R Lee1, M J Droller.   

Abstract

Transitional cell carcinoma of the bladder is comprised of a variety of cancer diatheses that manifest a spectrum of distinct biologic potentials. Although these diseases have traditionally been classified as "superficial" and "muscle invasive" on the basis of their histologic appearance (depth of penetration of the "bladder wall" and corresponding prognosis) the pathways presumably followed by the various forms of these cancers imply an even greater complexity. These disparate pathways may reflect different events in carcinogenesis, which may determine subsequent development and risk for either recurrence or progression. In addition, biologic activity and malignant potential for each type of cancer may be associated with distinctive molecular and genetic alterations. These considerations may provide an opportunity to expand traditional staging systems in creating molecular profiles that may more precisely characterize the biologic potential of these tumor diatheses. Although there are far more questions than answers concerning how these alterations may effect the natural history of bladder cancer, molecular-based identification of bladder cancer patients at greatest risk for progression may ultimately improve clinical management.

Entities:  

Mesh:

Year:  2000        PMID: 10696240     DOI: 10.1016/s0094-0143(05)70229-9

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  41 in total

1.  Improved objectivity of grading of T(A,1) transitional cell carcinomas of the urinary bladder by quantitative nuclear and proliferation related features.

Authors:  M G Bol; J P Baak; P C de Bruin; S Rep; W Marx; S Bos; O Kisman
Journal:  J Clin Pathol       Date:  2001-11       Impact factor: 3.411

Review 2.  Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC).

Authors:  Courtney Pollard; Steven C Smith; Dan Theodorescu
Journal:  Expert Rev Mol Med       Date:  2010-03-25       Impact factor: 5.600

3.  Apoptotic effect of the selective PPARβ/δ agonist GW501516 in invasive bladder cancer cells.

Authors:  Adeline Péchery; Sylvie Fauconnet; Hugues Bittard; Isabelle Lascombe
Journal:  Tumour Biol       Date:  2016-09-16

4.  Using urine microscopy and cytology for early detection of bladder cancer in male patients with lower urinary tract symptoms.

Authors:  Eddie S Y Chan; Chi-Fai Ng; See-Ming Hou; Sidney K H Yip
Journal:  Int Urol Nephrol       Date:  2010-11-04       Impact factor: 2.370

5.  Incidence and predictors of understaging in patients with clinical T1 urothelial carcinoma undergoing radical cystectomy.

Authors:  Jacob T Ark; Kirk A Keegan; Daniel A Barocas; Todd M Morgan; Matthew J Resnick; Chaochen You; Michael S Cookson; David F Penson; Rodney Davis; Peter E Clark; Joseph A Smith; Sam S Chang
Journal:  BJU Int       Date:  2014-04-03       Impact factor: 5.588

6.  Association study of the G-protein beta3 subunit C825T polymorphism with disease progression in patients with bladder cancer.

Authors:  Andreas Eisenhardt; Winfried Siffert; Dieter Rosskopf; Michael Musch; Max Mosters; Ulla Roggenbuck; Karl-Heinz Jöckel; Herbert Rübben; Gerd Lümmen
Journal:  World J Urol       Date:  2005-11-08       Impact factor: 4.226

7.  Comparison of the nuclear matrix protein 22 with voided urine cytology in the diagnosis of transitional cell carcinoma of the bladder.

Authors:  Murat Lekili; Ercüment Sener; Mehmet Akif Demir; Gökhan Temeltaş; Talha Müezzinoğlu; Coşkun Büyüksu
Journal:  Urol Res       Date:  2003-12-19

Review 8.  Quality of life aspects of bladder cancer: a review of the literature.

Authors:  M F Botteman; C L Pashos; R S Hauser; B L Laskin; A Redaelli
Journal:  Qual Life Res       Date:  2003-09       Impact factor: 4.147

Review 9.  Prognostic value of cell-cycle regulation biomarkers in bladder cancer.

Authors:  Anirban P Mitra; Donna E Hansel; Richard J Cote
Journal:  Semin Oncol       Date:  2012-10       Impact factor: 4.929

10.  CD10 expression in urothelial carcinoma of the bladder.

Authors:  Burak Bahadir; Kemal Behzatoglu; Sibel Bektas; Erol R Bozkurt; Sukru O Ozdamar
Journal:  Diagn Pathol       Date:  2009-11-16       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.